These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 30962053)
1. Dual sublingual immunotherapy with Japanese Cedar Pollen droplets and House Dust Mite tablets. Matsuoka T; Igarashi S; Kuroda Y; Fukano C; Natsui K; Doi-Ohashi K; Masuyama K Allergol Int; 2019 Oct; 68(4):533-535. PubMed ID: 30962053 [No Abstract] [Full Text] [Related]
2. Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet. Gotoh M; Okubo K; Yuta A; Ogawa Y; Nagakura H; Ueyama S; Ueyama T; Kawashima K; Yamamoto M; Fujieda S; Sakashita M; Sakamoto H; Iwasaki N; Mori E; Endo T; Ohta N; Kitazawa H; Okano M; Asako M; Takada M; Terada T; Inaka Y; Yonekura S; Matsuoka T; Kaneko S; Hata H; Hijikata N; Tanaka H; Masuyama K; Okamoto Y Allergol Int; 2020 Jan; 69(1):104-110. PubMed ID: 31421989 [TBL] [Abstract][Full Text] [Related]
3. Recent development on the use of sublingual immunotherapy tablets for allergic rhinitis. Waserman S; Shah A; Avilla E Ann Allergy Asthma Immunol; 2021 Aug; 127(2):165-175.e1. PubMed ID: 34029713 [TBL] [Abstract][Full Text] [Related]
4. Japanese cedar pollen sublingual immunotherapy is effective in treating seasonal allergic rhinitis during the pollen dispersal period for Japanese cedar and Japanese cypress. Yonekura S; Gotoh M; Okano M; Kurokawa T; Maekawa Y; Okubo K; Okamoto Y Allergol Int; 2022 Jan; 71(1):140-143. PubMed ID: 34509370 [No Abstract] [Full Text] [Related]
5. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis. Demoly P; Kleine-Tebbe J; Rehm D Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339 [TBL] [Abstract][Full Text] [Related]
6. Allergen Stability and Immunological Reactivity during Co-dissolution and Incubation of House Dust Mite and Japanese Cedar Pollen SLIT-Tablets. Watanabe A; Yamamoto T; Matsuhara H; Matsui H; Nakazawa H; Lund K; Ohashi-Doi K Biol Pharm Bull; 2020 Oct; 43(10):1448-1450. PubMed ID: 32759600 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024 [TBL] [Abstract][Full Text] [Related]
9. Treatment with the SQ house dust mite sublingual immunotherapy tablet may be initiated year-round. Nolte H; Bernstein DI; Kleine-Tebbe J; Fejerskov PA; Li Q; Lu S; Nelson HS J Allergy Clin Immunol Pract; 2018; 6(5):1758-1760.e1. PubMed ID: 29483037 [No Abstract] [Full Text] [Related]
10. The Effective Allergenic Reactivity of House Dust Mite Sublingual Immunotherapy Tablets Is Determined by Tablet Formulation. Kito H; Du W; Nakazawa H; Lund K; Ohashi-Doi K Biol Pharm Bull; 2019; 42(6):1030-1033. PubMed ID: 31155578 [TBL] [Abstract][Full Text] [Related]
12. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial. Devillier P; Fadel R; de Beaumont O Allergy; 2016 Feb; 71(2):249-57. PubMed ID: 26465232 [TBL] [Abstract][Full Text] [Related]
13. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial. Zieglmayer P; Nolte H; Nelson HS; Bernstein DI; Kaur A; Jacobi H; Lemell P; Schmutz R; Zieglmayer R; Horak F Ann Allergy Asthma Immunol; 2016 Dec; 117(6):690-696.e1. PubMed ID: 27979028 [TBL] [Abstract][Full Text] [Related]
14. Satisfaction of allergic patients treated with house dust mite sublingual immunotherapy. Aarestrup MF; Aarestrup PF; de Andrade MS; Aarestrup BJV; Nagato AC; Aarestrup FM Int J Immunopathol Pharmacol; 2021; 35():20587384211015528. PubMed ID: 33985377 [TBL] [Abstract][Full Text] [Related]
15. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy. Batard T; Baron-Bodo V; Martelet A; Le Mignon M; Lemoine P; Jain K; Mariano S; Horiot S; Chabre H; Harwanegg C; Marquette CA; Corgier BP; Soh WT; Satitsuksanoa P; Jacquet A; Chew FT; Nony E; Moingeon P Allergy; 2016 Feb; 71(2):220-9. PubMed ID: 26485347 [TBL] [Abstract][Full Text] [Related]
16. A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients. Hüser C; Dieterich P; Singh J; Shah-Hosseini K; Allekotte S; Lehmacher W; Compalati E; Mösges R Allergy; 2017 Jan; 72(1):77-84. PubMed ID: 27068870 [TBL] [Abstract][Full Text] [Related]
17. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947 [TBL] [Abstract][Full Text] [Related]
18. [A novel murine model of Japanese cedar pollinosis for characterizing allergen-specific sublingual immunotherapy]. Tofukuji S; Ishida S; Katayama K Nihon Yakurigaku Zasshi; 2017; 150(2):68-71. PubMed ID: 28794300 [No Abstract] [Full Text] [Related]
19. Analysis of factors influencing sensitization of Japanese cedar pollen in asymptomatic subjects. Sakaida H; Masuda S; Takeuchi K Auris Nasus Larynx; 2013 Dec; 40(6):543-7. PubMed ID: 23664584 [TBL] [Abstract][Full Text] [Related]
20. Safety evaluation of standardized allergen extract of Japanese cedar pollen for sublingual immunotherapy. Mitobe Y; Yokomoto Y; Ohashi-Doi K Regul Toxicol Pharmacol; 2015 Apr; 71(3):529-40. PubMed ID: 25701184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]